Yohei Kawaguchi

Dr. Yohei Kawaguchi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
YKYohei Kawaguchi
Yohei Kawaguchi
NNNanako Nishioka
Nanako Nishioka
TNTaiyo Nakamura
Taiyo Nakamura
KIKentaro Imai
Kentaro Imai
TATakuya Aoki
Takuya Aoki
NINorihiko Ikeda
Norihiko Ikeda
Original Article Impact of lymph node dissection on the efficacy of immune checkpoint inhibitors in patients with postoperative recurrence of non-small cell lung cancer Yohei Kawaguchi, Nanako Nishioka, Taiyo Nakamura, Kentaro Imai, Takuya Aoki, Naohiro Kajiwara, Norihiko Ikeda

12 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
YKYohei Kawaguchi
Yohei Kawaguchi
STSatoshi Takahashi
Satoshi Takahashi
YSYoshihisa Shimada
Yoshihisa Shimada
YKYujin Kudo
Yujin Kudo
NINorihiko Ikeda
Norihiko Ikeda
Oligometastatic non-small cell lung cancer (omNSCLC) is increasingly recognized as a clinically actionable subset, characterized by a limited number of metastatic lesions and the potential to benefit from combined systemic and local treatments. Advances in systemic therapy, particularly immune checkpoint inhibitors (ICI) and molecular targeted agents, have led to prolonged disease control in selected patients. Prospective clinical trials have shown that incorporating local therapy into systemic treatment can improve progression-free and overall survival outcomes in carefully selected patients with metastatic disease. Radiotherapy has increasingly become the preferred modality for local consolidation, especially when surgical options are limited or impractical. Key factors influencing treatment selection include biomarker status, the number and distribution of metastases, and the response to the initial systemic therapy. The optimal timing and modality of local interventions remain under investigation. This review examines the evolving treatment strategies for omNSCLC, primarily from the perspective of systemic therapies. By contextualizing local treatment modalities within the framework of immunotherapy and targeted therapy, we reinterpret current evidence to clarify when and how local therapy contributes to long-term disease control.

1 May 2024 in Oxford Medical Case Reports
Verified
Journal Article
Open access
PDF file
RTRena Tamenaga
Rena Tamenaga
YKYohei Kawaguchi
Yohei Kawaguchi
MKMariko Kogami
Mariko Kogami
TKTaro Kufukihara
Taro Kufukihara
RMReimi Mizushima
Reimi Mizushima
KAKazutetsu Aoshiba
Kazutetsu Aoshiba
While lung cancer is the predominant neoplasm causing hemoptysis, rare benign neoplasms can also be associated with hemoptysis. A 60-year-old woman presented with cough and hemoptysis. Chest computed tomography revealed an oval-shaped, well-circumscribed solitary mass (10 cm in size) in the right lower lobe, which had grown rapidly over the past year. The presence of intramass air bubbles and a surrounding halo of ground-glass opacities suggested the hemorrhagic rupture of a circumscribed hematoma into the surrounding lung tissue. Subsequent right lower lobectomy revealed a well-demarcated hematoma; its wall consisted of nonatypical spindle tumor cells, which were histologically diagnosed as meningioma. No meningioma was observed in the central nervous system, leading to the diagnosis of primary pulmonary meningioma. This case highlights PPM as a rare benign tumor (World Health Organization grade 1) capable of rapid development due to intratumoral hemorrhage, presenting with hemoptysis.

23 February 2025 in Cureus
Verified
Journal Article
Open access
YKYohei Kawaguchi
Yohei Kawaguchi
MNMunehide Nakatsugawa
Munehide Nakatsugawa
NNNanako Nishioka
Nanako Nishioka
TNTaiyo Nakamura
Taiyo Nakamura
KIKentaro Imai
Kentaro Imai
NINorihiko Ikeda
Norihiko Ikeda

6 May 2025 in Cureus
Verified
Journal Article
Open access
PDF file
TNTaiyo Nakamura
Taiyo Nakamura
YKYohei Kawaguchi
Yohei Kawaguchi
JOJiyunichirou Oosawa
Jiyunichirou Oosawa
KIKentaro Imai
Kentaro Imai
TATakuya Aoki
Takuya Aoki
NINorihiko Ikeda
Norihiko Ikeda
Background The optimal duration of immune checkpoint inhibitor (ICI) therapy for maximum benefits remains unclear. Recently, the long-term follow-up data from clinical trials suggest the existence of a durable response (DR) that maintains the therapeutic effect even after ICI discontinuation. The study aimed to explore how the characteristics of ICI therapy influence the effectiveness of subsequent treatments in patients with advanced non-small-cell lung cancer (NSCLC). Methods The medical records of 134 patients with NSCLC who received ICIs before December 31, 2022, were retrospectively reviewed. We evaluated the impact of pretreatment ICIs on survival after completion of ICI administration. Results Among the 116 included patients, long ICI use (≥180 days) was the only independent prognostic factor for post-ICI overall survival (OS) in the multivariate analysis (HR: 0.382, 95% CI: 0.206-0.708, p=0.002). Patients who received ICIs for < 180 days showed significantly improved survival with subsequent chemotherapy (SC) compared to those who received only best supportive care (BSC) (p<0.001). However, among patients treated with ICIs for ≥ 180 days, no significant difference in OS or post-ICI OS was observed between the SC and BSC groups (p=0.188). In patients who discontinued ICIs due to PD, the impact of ICI treatment duration on survival outcomes differed. Among those with short ICI use, the SC group showed significantly better post-ICI OS compared to the BSC group (p=0.007). However, in patients with long ICI use, there was no significant difference in post-ICI OS between the SC and BSC groups (p=0.913). Regarding OS, no statistically significant differences were observed between the SC and BSC groups, regardless of ICI treatment duration. The 2-year OS was 47.6% in the SC group and 46.0% in the BSC group among patients with short ICI use (p=0.549), and 93.3% vs. 66.7% among those with long ICI use (p=0.136). Similarly, in patients who discontinued ICIs without PD, survival outcomes varied depending on ICI duration. Among those with short ICI use, the BSC group had a 2-year post-ICI OS of 21.1%, which was lower than that of the SC group (50.0%; p=0.08). The 2-year OS was also significantly higher in the SC group (64.3%) compared to the BSC group (31.6%; p=0.008). In contrast, no significant differences were observed in post-ICI OS (p=0.104) or OS (64.3% vs. 31.6%; p=0.104) between the SC and BSC groups among patients with long ICI use. Conclusion The achievement of a DR through prolonged ICI use may reduce the need for immediate subsequent chemotherapy in selected patients.